News

Deal Announcements

Deltanoid Pharma Nets $12 Million Series B

Wednesday, December 19, 2007 5:28:00 AM PDT | VentureDeal Staff
MADISON, WI -- Deltanoid Pharmaceuticals, Inc. announced that it has raised $12 million in second round venture capital funding.

Deltanoid is developing treatments for osteoporosis, renal osteodystrophy, psoriasis and other related diseases.  The company is focused on designing advanced vitamin D-based therapies that are already in human clinical trials.

Investors in the round included the Wisconsin Alumni Research Foundation, Mason Wells and Venture Investors.

The company said it plans to use the funding proceeds to advance its lead candidates and preclinical pipeline for therapies to treat patients with renal disease.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1